Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
BioVie (BIVI) +365% Upside to $5.25 Target – Clinical Catalysts in Focus

BioVie (BIVI) +365% Upside to $5.25 Target – Clinical Catalysts in Focus

Key Takeaways

  • The central price target used here is $5.25, calculated as the arithmetic mean of two verified analyst targets of $5.00 and $5.51.
  • With BioVie trading near $1.13, reaching $5.25 would require roughly a 365% upside, a very large move.
  • Coverage is thin: only two analysts tracked by S&P Global publish targets, and the target range is $5.00 to $5.51.
  • Supporting factors include clinical readouts for bezisterim (NE3107) in Parkinson's disease and Long COVID, plus BIV201's orphan-drug and Fast Track status.
  • Key risks are a short cash runway, dilution and reverse-split history, and binary clinical-trial outcomes.
  • For more context, explore this ticker's Major News, Today's Price Move, Forecast, and Earnings pages.

What Analysts Are Saying About BIVI

BioVie Inc. (BIVI) is a clinical-stage biopharmaceutical company developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), is being studied in Parkinson's disease, Long COVID, and Alzheimer's disease, while BIV201 (continuous-infusion terlipressin) targets refractory ascites.

Analyst coverage of this micro-cap stock is limited. Two analysts tracked by S&P Global have published 12-month price targets of $5.00 and $5.51, producing a mean of approximately $5.26, which we round to a clean central target of $5.25. The rating carries a "Strong Buy" designation. The narrow dollar range ($5.00 to $5.51) reflects consensus on the scale of potential upside rather than strong disagreement, but the small sample size means the figure should be treated with caution rather than as a broad Wall Street consensus. Other aggregators report fewer or no current targets, underscoring how lightly followed the name is. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

The latest verified market price is about $1.13, within a 52-week range of $0.82 to $3.79. Reaching $5.25 would require a gain of roughly 365%, which is a very large move for any equity and especially demanding for a pre-revenue biotechnology company. The path would almost certainly depend on positive clinical data or a strategic partnership, because the company does not currently generate product revenue and is valued at a market capitalization of only about $12 million.

What Could Support a Move Toward the Target

The most important drivers are clinical catalysts. Bezisterim is an oral candidate designed to cross the blood-brain barrier and reduce neuroinflammation and insulin resistance. Positive topline results from the SUNRISE-PD trial in early Parkinson's disease or the ADDRESS-LC trial in Long COVID could materially change the risk-reward profile. In liver disease, BIV201 holds FDA (U.S. Food and Drug Administration) Orphan Drug and Fast Track designations, with a planned Phase 3 trial in cirrhosis and ascites. A partnership, licensing deal, or non-dilutive funding would also strengthen the balance sheet and sentiment.

What Could Prevent the Target From Being Reached

The principal obstacles are financial and scientific. BioVie has a short estimated cash runway, and its history includes a 1-for-10 reverse stock split in July 2025 aimed at maintaining Nasdaq's minimum bid-price requirement. Persistent cash burn creates ongoing dilution risk, and a failed or inconclusive clinical trial could sharply compress the share price. As a micro-cap with thin liquidity, the stock is also vulnerable to outsized volatility on modest news flow.

Technical Levels and Market Structure

The $1.00 level is psychologically significant given the company's listing-compliance history, while the 52-week low of $0.82 is the nearest notable support level. On the upside, the 52-week high of $3.79 represents a meaningful prior ceiling that would need to be cleared well before any move toward $5.25. The stock trades near the lower portion of its annual range, reflecting the current uncertainty around its pipeline.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though no explicit horizon was disclosed with these targets. Investors should watch topline data from the SUNRISE-PD and ADDRESS-LC trials, updates on BIV201's Phase 3 program, financing announcements and cash-burn commentary in quarterly reports, and any Nasdaq listing-compliance developments. These events, rather than broad market trends, are likely to determine the trajectory toward or away from the $5.25 level. From what I see, monitoring these milestones is essential for any position in this name.

Exploring AI Daily Buy/Sell Signals

In my view, Tickeron's AI Daily Buy/Sell Signals provide a practical way to stay on top of names like this. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For a volatile, thinly traded name like BIVI, systematic signal monitoring can add useful context alongside fundamental research.

Final Assessment

The $5.25 central target is an analyst-derived average built from only two published targets, and it sits roughly 365% above the current price, making the required move very large. The upside rests almost entirely on clinical success for bezisterim or BIV201, or on a transformational partnership. Against that stand a short cash runway, ongoing dilution risk, and binary trial outcomes that could as easily compress the share price as lift it. With such thin coverage and no revenue base, the $5.25 figure is best understood as a scenario-based estimate rather than a probable outcome, and investors should monitor the clinical and financing calendar closely. I’m watching this closely as new data emerges.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BIVI

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


BIVI in +9.77% Uptrend, growing for three consecutive days on October 28, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BIVI advanced for three days, in 194 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BIVI's RSI Oscillator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BIVI as a result. In 83 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for BIVI turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 39 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

BIVI moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for BIVI moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

BIVI broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BIVI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.105) is normal, around the industry mean (3.498). P/E Ratio (-0.436) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. BIVI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
680 W Nye Lane
Phone
+1 775 888-3162
Employees
13
Web
https://www.bioviepharma.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.